Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
Department of Plastic Surgery, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
Anticancer Res. 2014 Sep;34(9):5217-20.
BACKGROUND/AIM: There were two aims in the present study. The first was to evaluate the usefulness of insulin-like growth factor 1 (IGF1) for melanoma detection. The second was to correlate changes of serum levels of IGF1 with the Breslow score and sentinel node metastasis positivity.
We examined a group of 216 cases, 77 patients with melanomas and 139 healthy probands. We determined the serum IGF1 levels of each patient using an IRMA radioisotope IGF1 assay kit. Serum samples were collected prior to surgery or any other form of treatment. All melanoma diagnoses were histologically verified.
Based on the statistical evaluation between the melanoma group and group of healthy individuals, we observed statistically significant differences in IGF1 serum levels. The median IGF1 levels in the melanoma group was 154.1 ng/ml compared to 111.2 ng/ml in the group of healthy individuals (p=0.0036). The changes of the IGF1 levels related to the Breslow score categories were statistically significant (p=0.0027). Lastly, we compared the results between the positive and negative metastatic affection of the sentinel nodes. The median IGF1 levels in the negative group was 173.5 ng/ml compared to 205.8 ng/ml in the positive group. This difference was statistically significant (p=0.0407).
Serum levels of IGF1 were significantly higher in patients diagnosed with melanoma compared to the healthy control group. The changes of the IGF1 levels related to the Breslow score categories were statistically significant. Serum levels of IGF1 were significantly higher in the group with the positive metastatic affection of the sentinel nodes than in negative patients.
背景/目的：本研究有两个目的。第一个目的是评估胰岛素样生长因子 1（IGF1）在黑色素瘤检测中的作用。第二个目的是将 IGF1 血清水平的变化与 Breslow 评分和前哨淋巴结转移阳性相关联。
我们检查了 216 例患者，包括 77 例黑色素瘤患者和 139 例健康对照者。我们使用 IRMA 放射性同位素 IGF1 检测试剂盒测定每位患者的血清 IGF1 水平。血清样本在手术或任何其他治疗之前采集。所有黑色素瘤诊断均经组织学证实。
基于黑色素瘤组和健康个体组之间的统计评估，我们观察到 IGF1 血清水平存在统计学显著差异。黑色素瘤组 IGF1 中位数为 154.1ng/ml，健康个体组为 111.2ng/ml（p=0.0036）。IGF1 水平与 Breslow 评分类别的变化具有统计学意义（p=0.0027）。最后，我们比较了前哨淋巴结转移阳性和阴性组的结果。阴性组 IGF1 中位数为 173.5ng/ml，阳性组为 205.8ng/ml。这种差异具有统计学意义（p=0.0407）。
与健康对照组相比，诊断为黑色素瘤的患者血清 IGF1 水平显著升高。IGF1 水平的变化与 Breslow 评分类别相关，具有统计学意义。前哨淋巴结转移阳性组患者的 IGF1 血清水平显著高于阴性患者。
